Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

PT-141

Bremelanotide, Vyleesi

Quick Stats
Studies 74
Trials 10
Score 3
2021 pubmed 43 citations

Structural insights into ligand recognition and activation of the melanocortin-4 receptor.

Zhang. Huibing H; Chen. Li-Nan LN; Yang. Dehua D; Mao. Chunyou C; Shen. Qingya Q; Feng. Wenbo W; Shen. Dan-Dan DD; Dai. Antao A; Xie. Shanshan S; Zhou. Yan Y; Qin. Jiao J; Sun. Jin-Peng JP; Scharf. Daniel H DH; Hou. Tingjun T; Zhou. Tianhua T; Wang. Ming-Wei MW; Zhang. Yan Y

Key Findings

  • High‑resolution structures of MC4R bound to α‑MSH, afamelanotide, bremelanotide, and the small‑molecule THIQ were solved
  • Peptide agonists share a conserved binding pocket while the small‑molecule uses a distinct site, explaining selectivity
  • A unique activation mechanism for MC4R was identified, shedding light on how the receptor couples to G‑proteins

Practical Outcomes

  • The detailed binding info can guide the design of more selective MC4R‑targeting drugs, potentially leading to safer, more effective weight‑management or performance agents. For now, it doesn’t change how you’d dose existing peptides like pt‑141, but it signals future improvements.

Summary

Scientists mapped the exact shape of the MC4R protein when it’s hooked up to its natural hormone and to drugs like bremelanotide (pt‑141). This shows how these molecules stick to the receptor and turn it on, giving clues for making better weight‑loss or performance‑boosting compounds.

Abstract

Melanocortin-4 receptor (MC4R) plays a central role in the regulation of energy homeostasis. Its high sequence similarity to other MC receptor family members, low agonist selectivity and the lack of structural information concerning MC4R-specific activation have hampered the development of MC4R-seletive therapeutics to treat obesity. Here, we report four high-resolution structures of full-length MC4R in complex with the heterotrimeric G<sub>s</sub> protein stimulated by the endogenous peptide ligand &#x3b1;-MSH, FDA-approved drugs afamelanotide (Scenesse&#x2122;) and bremelanotide (Vyleesi&#x2122;), and a selective small-molecule ligand THIQ, respectively. Together with pharmacological studies, our results reveal the conserved binding mode of peptidic agonists, the distinctive molecular details of small-molecule agonist recognition underlying receptor subtype selectivity, and a distinct activation mechanism for MC4R, thereby offering new insights into G protein coupling. Our work may facilitate the discovery of selective therapeutic agents targeting MC4R.

Study Information

Provider

pubmed

Year

2021

Date

2021-08-25T00:00:00.000Z

DOI

10.1038/s41422-021-00552-3

Citations

43

References

91